PharmaEssentia Corporation
6446
株式のランク
#1431
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
株価
$37.20
時価総額
$15.39B
変化（1日）
-0.43%
変化（1年）
146.23%
国
TW
取引 PharmaEssentia Corporation (6446)
カテゴリー
Healthcare
PharmaEssentia Corporation（6446）の配当履歴
PharmaEssentia Corporation（証券コード：6446）は合計で1回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$0.99
配当利回り（TTM）：0.0012
すべての配当の合計（株式分割調整済み）は：$0.99
配当利回り（TTM）：0.0012
2025から2026までのPharmaEssentia Corporation（6446）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $0.9898 | 0.00% |
| 2025 | $0.9898 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.10 | 0.00% |
| 2025 | $1.10 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 38.00% |
IN
|
